Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Muhammad Junaid, Cheng-Dong Li, Jiayi Li, Abbas Khan, Syed Shujait Ali, Syed Baber Jamal, Shah Saud, Arif Ali & Dong-Qing Wei. (2021) Structural insights of catalytic mechanism in mutant pyrazinamidase of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics 39:9, pages 3172-3185.
Read now
Read now
Gaurava Srivastava, M. P. Darokar & Ashok Sharma. (2020) Molecular investigation against the resistant mechanism of PncA mutated pyrazinamide resistance and insight into the role of pH environment for pyrazinamide activation. Journal of Biomolecular Structure and Dynamics 38:11, pages 3411-3431.
Read now
Read now
Muhammad Tahir Khan & Shaukat Iqbal Malik. (2020) Structural dynamics behind variants in pyrazinamidase and pyrazinamide resistance. Journal of Biomolecular Structure and Dynamics 38:10, pages 3003-3017.
Read now
Read now
HM Adnan Hameed, Yaoju Tan, Md Mahmudul Islam, Zhili Lu, Chiranjibi Chhotaray, Shuai Wang, Zhiyong Liu, Cuiting Fang, Shouyong Tan, Wing Wai Yew, Nanshan Zhong, Jianxiong Liu & Tianyu Zhang. (2020) Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China. Infection and Drug Resistance 13, pages 217-227.
Read now
Read now
Patricia Bento da Silva, Débora Leite Campos, Camila Maríngolo Ribeiro, Isabel Cristiane da Silva & Fernando Rogério Pavan. (2017) New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001–2016). Expert Opinion on Therapeutic Patents 27:3, pages 269-282.
Read now
Read now
Shuo Zhang, Jiazhen Chen, Wanliang Shi, Peng Cui, Jia Zhang, Sanghyun Cho, Wenhong Zhang & Ying Zhang. (2017) Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging Microbes & Infections 6:1, pages 1-2.
Read now
Read now
Anna Engström. (2016) Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis. Infectious Diseases 48:1, pages 1-17.
Read now
Read now
Matthias Stehr, Ayssar A Elamin & Mahavir Singh. (2015) Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. Expert Review of Anti-infective Therapy 13:5, pages 593-603.
Read now
Read now
Muhammad Tahir Khan, Elise Dumont, Aijaz Rasool Chaudhry & Dong-Qing Wei. Free energy landscape and thermodynamics properties of novel mutations in PncA of pyrazinamide resistance isolates of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-12.
Read now
Read now
Articles from other publishers (99)
Fabio L. Fontes, Steven A. Rooker, Jamie K. Lynn-Barbe, Michael A. Lyons, Debbie C. Crans & Dean C. Crick. (2024) Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores. Frontiers in Molecular Biosciences 11.
Crossref
Crossref
Biplab Singha, Sumit Murmu, Tripti Nair, Rahul Singh Rawat, Aditya Kumar Sharma & Vijay Soni. (2024) Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance. Metabolites 14:1, pages 63.
Crossref
Crossref
Ghada Bouz, Petr Šlechta, Ondřej Jand’ourek, Klára Konečná, Pavla Paterová, Pavel Bárta, Martin Novák, Radim Kučera, Nils-Jørgen Knudsen Dal, Federico Fenaroli, Júlia Zemanová, Martin Forbak, Jana Korduláková, Oto Pavliš, Pavla Kubíčková, Martin Doležal & Jan Zitko. (2022) Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid. ACS Infectious Diseases 9:1, pages 79-96.
Crossref
Crossref
Kareem A. Ibrahim, Mona T. Kashef, Tharwat R. Elkhamissy, Mohammed A. Ramadan & Omneya M. Helmy. (2022) Aspartate α-decarboxylase a new therapeutic target in the fight against Helicobacter pylori infection. Frontiers in Microbiology 13.
Crossref
Crossref
Pooja V. Hegde, Wassihun W. Aragaw, Malcolm S. Cole, Gorakhnath Jachak, Priya Ragunathan, Sachin Sharma, Amaravadhi Harikishore, Gerhard Grüber, Thomas Dick & Courtney C. Aldrich. (2022) Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents. Bioorganic & Medicinal Chemistry 74, pages 117046.
Crossref
Crossref
Ananthi Rajendran & Kannan Palaniyandi. (2022) Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. Current Microbiology 79:11.
Crossref
Crossref
Omar H. Badie, Ahmed F. Basyony & Reham Samir. (2022) Computer-Based Identification of Potential Druggable Targets in Multidrug-Resistant Acinetobacter baumannii: A Combined In Silico, In Vitro and In Vivo Study. Microorganisms 10:10, pages 1973.
Crossref
Crossref
Yangming Ding, Hui Zhu, Lei Fu, Weiyan Zhang, Bin Wang, Shaochen Guo, Xi Chen, Ning Wang, Haiting Liu & Yu Lu. (2022) Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy 66:9.
Crossref
Crossref
Wuan-Geok Saw, Chen Yen Leow, Amaravadhi Harikishore, Joon Shin, Malcolm S. Cole, Wassihun Wedajo Aragaw, Priya Ragunathan, Pooja Hegde, Courtney C. Aldrich, Thomas Dick & Gerhard Grüber. (2022)
Structural and Mechanistic Insights into
Mycobacterium abscessus
Aspartate Decarboxylase PanD and a Pyrazinoic Acid-Derived Inhibitor
. ACS Infectious Diseases 8:7, pages 1324-1335.
Crossref
Crossref
S. Alghamdi & M. Asif. (2022) Pyrazinamide Analogs Designed for Rational Drug Designing Strategies against Resistant Tuberculosis. Russian Journal of Bioorganic Chemistry 48:3, pages 491-512.
Crossref
Crossref
Pierre Santucci, Beren Aylan, Laure Botella, Elliott M. Bernard, Claudio Bussi, Enrica Pellegrino, Natalia Athanasiadi & Maximiliano G. Gutierrez. (2022) Visualizing Pyrazinamide Action by Live Single-Cell Imaging of Phagosome Acidification and Mycobacterium tuberculosis pH Homeostasis. mBio 13:2.
Crossref
Crossref
Christoph Grohmann, Danushka S. Marapana & Gregor Ebert. (2021) Targeted protein degradation at the host–pathogen interface. Molecular Microbiology 117:3, pages 670-681.
Crossref
Crossref
Joshua M. Thiede, Nicholas A. Dillon, Michael D. Howe, Ranee Aflakpui, Samuel J. Modlin, Sven E. Hoffner, Faramarz Valafar, Yusuke Minato & Anthony D. Baughn. (2022) Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis. mBio 13:1.
Crossref
Crossref
Michael G. Whitfield, David M. Engelthaler, Christopher Allender, Megan Folkerts, Tim H. Heupink, Jason Limberis, Robin M. Warren, Annelies Van Rie & John Z. Metcalfe. (2022) Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology 60:1.
Crossref
Crossref
Taoping Weng, Feng Sun, Yang Li, Jiazhen Chen, Xinchang Chen, Rong Li, Shijia Ge, Yanlin Zhao & Wenhong Zhang. (2021) Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infectious Diseases 21:1.
Crossref
Crossref
Saad Alghamdi & Mohammad Asif. 2021. Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex. Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex.
Matthew Powell, Mark A. T. Blaskovich & Karl A. Hansford. (2021) Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?. ACS Infectious Diseases 7:8, pages 2050-2067.
Crossref
Crossref
Claudia Perea, Giovanna Ciaravino, Tod Stuber, Tyler C. Thacker, Suelee Robbe-Austerman, Alberto Allepuz & Bernat Pérez de Val. (2021) Whole-Genome SNP Analysis Identifies Putative Mycobacterium bovis Transmission Clusters in Livestock and Wildlife in Catalonia, Spain. Microorganisms 9:8, pages 1629.
Crossref
Crossref
Wanliang Shi. (2021) Activity of Pyrazinamide against Mycobacterium tuberculosis at Neutral pH in PZA-S1 Minimal Medium. Antibiotics 10:8, pages 909.
Crossref
Crossref
Pierre Santucci, Daniel J. Greenwood, Antony Fearns, Kai Chen, Haibo Jiang & Maximiliano G. Gutierrez. (2021) Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. Nature Communications 12:1.
Crossref
Crossref
Priya Ragunathan, Malcolm Cole, Chitra Latka, Wassihun Wedajo Aragaw, Pooja Hegde, Joon Shin, Malathy Sony Subramanian Manimekalai, Sankaranarayanan Rishikesan, Courtney C. Aldrich, Thomas Dick & Gerhard Grüber. (2021)
Mycobacterium tuberculosis
PanD Structure–Function Analysis and Identification of a Potent Pyrazinoic Acid-Derived Enzyme Inhibitor
. ACS Chemical Biology 16:6, pages 1030-1039.
Crossref
Crossref
Aditi Chauhan, Manoj Kumar, Awanish Kumar & Kajal Kanchan. (2021) Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs. Life Sciences 274, pages 119301.
Crossref
Crossref
Asma Sindhoo Nangraj, Abbas Khan, Shaheena Umbreen, Sana Sahar, Maryam Arshad, Saba Younas, Sajjad Ahmad, Shahid Ali, Syed Shujait Ali, Liaqat Ali & Dong-Qing Wei. (2021) Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Donald J. AbrahamCourtney C. Aldrich, Robert S. Wallis, Rory P. Remmel, Pooja Hegde & Christina L. Stallings. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
110
.
A. G. Naumov & A. V. Pavlunin. (2021) Mechanisms of development of medicine stability <i>Mycobacterium tuberculosis</i>: is there a chance to win?. PULMONOLOGIYA 31:1, pages 100-108.
Crossref
Crossref
Erik J. Hasenoehrl, Thomas J. Wiggins & Michael Berney. (2021) Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Taimoor Khan, Abbas Khan, Syed Shujait Ali, Shahid Ali & Dong-Qing Wei. (2021)
A computational perspective on the dynamic behaviour of recurrent drug resistance mutations in the pncA gene from
Mycobacterium tuberculosis
. RSC Advances 11:4, pages 2476-2486.
Crossref
Crossref
Laura Carreto-Binaghi, Yolanda González & Silvia Guzmán-Beltrán. (2021) Enfermedad pulmonar causada por micobacterias no tuberculosas: diagnóstico, tratamiento y mecanismos de resistencia a los antimicrobianos. NCT Neumología y Cirugía de Tórax 80:2, pages 141-153.
Crossref
Crossref
Bernat Coll-Martínez, Antonio Delgado & Bernat Crosas. (2020) The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents. Molecules 25:24, pages 5956.
Crossref
Crossref
Hailey S. Butman, Timothy J. Kotzé, Cynthia S. Dowd & Erick Strauss. (2020) Vitamin in the Crosshairs: Targeting Pantothenate and Coenzyme A Biosynthesis for New Antituberculosis Agents. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Fabio L. Fontes, Benjamin J. Peters, Debbie C. Crans & Dean C. Crick. (2020)
The Acid–Base Equilibrium of Pyrazinoic Acid Drives the pH Dependence of Pyrazinamide-Induced
Mycobacterium tuberculosis
Growth Inhibition
. ACS Infectious Diseases 6:11, pages 3004-3014.
Crossref
Crossref
Muhammad Tahir Khan, Sathishkumar Chinnasamy, Zhilei Cui, Muhammad Irfan & Dong-Qing Wei. (2020) Mechanistic analysis of A46V, H57Y, and D129N in pyrazinamidase associated with pyrazinamide resistance. Saudi Journal of Biological Sciences 27:11, pages 3150-3156.
Crossref
Crossref
Gajendra Pratap Singh, Madhuri Jha, Mamtesh Singh & Naina. (2020) Modeling the mechanism pathways of first line drug in Tuberculosis using Petri nets. International Journal of System Assurance Engineering and Management 11:S2, pages 313-324.
Crossref
Crossref
Elise A. Lamont, Nicholas A. Dillon & Anthony D. Baughn. (2020) The Bewildering Antitubercular Action of Pyrazinamide. Microbiology and Molecular Biology Reviews 84:2.
Crossref
Crossref
Pooja Gopal & Thomas Dick. (2020) Targeted protein degradation in antibacterial drug discovery?. Progress in Biophysics and Molecular Biology 152, pages 10-14.
Crossref
Crossref
Pooja Gopal, Jickky Palmae Sarathy, Michelle Yee, Priya Ragunathan, Joon Shin, Shashi Bhushan, Junhao Zhu, Tatos Akopian, Olga Kandror, Teck Kwang Lim, Martin Gengenbacher, Qingsong Lin, Eric J. Rubin, Gerhard Grüber & Thomas Dick. (2020) Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nature Communications 11:1.
Crossref
Crossref
Nayera W. Hassan, Manal N. Saudi, Yasser S. Abdel-Ghany, Azza Ismail, Perihan A. Elzahhar, Dharmarajan Sriram, Rasha Nassra, Marwa M. Abdel-Aziz & Soad A. El-Hawash. (2020) Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies. Bioorganic Chemistry 96, pages 103610.
Crossref
Crossref
Malancha Karmakar, Carlos H. M. Rodrigues, Kristy Horan, Justin T. Denholm & David B. Ascher. (2020) Structure guided prediction of Pyrazinamide resistance mutations in pncA. Scientific Reports 10:1.
Crossref
Crossref
Abbas Khan, Ashfaq-Ur-Rehman, Muhammad Junaid, Cheng-Dong Li, Shoaib Saleem, Fahad Humayun, Shazia Shamas, Syed Shujait Ali, Zainib Babar & Dong-Qing Wei. (2020) Dynamics Insights Into the Gain of Flexibility by Helix-12 in ESR1 as a Mechanism of Resistance to Drugs in Breast Cancer Cell Lines. Frontiers in Molecular Biosciences 6.
Crossref
Crossref
Qingan Sun, Xiaojun Li, Lisa M. Perez, Wanliang Shi, Ying Zhang & James C. Sacchettini. (2020) The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nature Communications 11:1.
Crossref
Crossref
Aamir Mehmood, Muhammad Tahir Khan, Aman Chandra Kaushik, Anwar Sheed Khan, Muhammad Irfan & Dong-Qing Wei. (2019) Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance. Frontiers in Bioengineering and Biotechnology 7.
Crossref
Crossref
Pooja Gopal, Gerhard Grüber, Véronique Dartois & Thomas Dick. (2019) Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. Trends in Pharmacological Sciences 40:12, pages 930-940.
Crossref
Crossref
Lei He, Peng Cui, Wanliang Shi, Qiong Li, Wenhong Zhang, Min Li & Ying Zhang. (2019) Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) in Mycobacterium tuberculosis by Competing with tmRNA. Pathogens 8:4, pages 230.
Crossref
Crossref
Timothy J. de Wet, Digby F. Warner & Valerie Mizrahi. (2019) Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery. Accounts of Chemical Research 52:8, pages 2340-2348.
Crossref
Crossref
Xinchang Chen, Guiqing He, Shiyong Wang, Siran Lin, Jiazhen Chen & Wenhong Zhang. (2019) Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance Mycobacterium tuberculosis Isolates From China. Frontiers in Microbiology 10.
Crossref
Crossref
Wanliang Shi, Peng Cui, Hongxia Niu, Shuo Zhang, Tone Tønjum, Bingdong Zhu & Ying Zhang. (2019) Introducing RpsA Point Mutations Δ438A and D123A into the Chromosome of Mycobacterium tuberculosis Confirms Their Role in Causing Resistance to Pyrazinamide. Antimicrobial Agents and Chemotherapy 63:6.
Crossref
Crossref
Muhammad Tahir Khan, Abbas Khan, Ashfaq Ur Rehman, Yanjie Wang, Khalid Akhtar, Shaukat Iqbal Malik & Dong-Qing Wei. (2019) Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance. Scientific Reports 9:1.
Crossref
Crossref
Aditi Singh, Pallavi Somvanshi & Abhinav Grover. (2018)
Pyrazinamide drug resistance in RpsA mutant (∆438A) of
Mycobacterium tuberculosis
: Dynamics of essential motions and free‐energy landscape analysis
. Journal of Cellular Biochemistry 120:5, pages 7386-7402.
Crossref
Crossref
Muhammad Tahir Khan, Muhammad Junaid, Xueying Mao, Yanjie Wang, Abid Hussain, Shaukat Iqbal Malik & Dong‐Qing Wei. (2018)
Pyrazinamide resistance and mutations L19R, R140H, and E144K in
Pyrazinamidase
of
Mycobacterium tuberculosis
. Journal of Cellular Biochemistry 120:5, pages 7154-7166.
Crossref
Crossref
Ghada Bouz, Lucia Semelková, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Lucie Navrátilová, Vladimír Kubíček, Jiří Kuneš, Martin Doležal & Jan Zitko. (2019) Derivatives of 3-Aminopyrazine-2-carboxamides: Synthesis, Antimicrobial Evaluation, and in Vitro Cytotoxicity. Molecules 24:7, pages 1212.
Crossref
Crossref
Muhammad Junaid, Muhammad Tahir Khan, Shaukat Iqbal Malik & Dong-Qing Wei. (2018) Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N. Journal of Chemical Information and Modeling 59:1, pages 498-508.
Crossref
Crossref
Paolo Miotto, Ying Zhang, Daniela Maria Cirillo & Wing Cheong Yam. (2018) Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology 23:12, pages 1098-1113.
Crossref
Crossref
Thomas Lane, Daniel P. Russo, Kimberley M. Zorn, Alex M. Clark, Alexandru Korotcov, Valery Tkachenko, Robert C. Reynolds, Alexander L. Perryman, Joel S. Freundlich & Sean Ekins. (2018)
Comparing and Validating Machine Learning Models for
Mycobacterium tuberculosis
Drug Discovery
. Molecular Pharmaceutics 15:10, pages 4346-4360.
Crossref
Crossref
Jan Zitko, Alžběta Mindlová, Ondřej Valášek, Ondřej Jand’ourek, Pavla Paterová, Jiří Janoušek, Klára Konečná & Martin Doležal. (2018) Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents. Molecules 23:9, pages 2390.
Crossref
Crossref
W. Liu, J. Chen, Y. Shen, J. Jin, J. Wu, F. Sun, Y. Wu, L. Xie, Y. Zhang & W. Zhang. (2018) Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clinical Microbiology and Infection 24:9, pages 1016.e1-1016.e5.
Crossref
Crossref
Wanliang Shi, Jiazhen Chen, Shuo Zhang, Wenhong Zhang & Ying Zhang. (2018)
Identification of Novel Mutations in LprG (
rv1411c
),
rv0521
,
rv3630
,
rv0010c
,
ppsC
, and
cyp128
Associated with Pyrazinoic Acid/Pyrazinamide Resistance in Mycobacterium tuberculosis
. Antimicrobial Agents and Chemotherapy 62:7.
Crossref
Crossref
Eyob Abera Mesfin, Dereje Beyene, Abreham Tesfaye, Addisu Admasu, Desalegn Addise, Miskir Amare, Biniyam Dagne, Zelalem Yaregal, Ephrem Tesfaye & Belay Tessema. (2018) Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLOS ONE 13:6, pages e0197737.
Crossref
Crossref
Tania J. Lupoli, Julien Vaubourgeix, Kristin Burns-Huang & Ben Gold. (2018) Targeting the Proteostasis Network for Mycobacterial Drug Discovery. ACS Infectious Diseases 4:4, pages 478-498.
Crossref
Crossref
H. M. Adnan Hameed, Md Mahmudul Islam, Chiranjibi Chhotaray, Changwei Wang, Yang Liu, Yaoju Tan, Xinjie Li, Shouyong Tan, Vincent Delorme, Wing W. Yew, Jianxiong Liu & Tianyu Zhang. (2018) Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. Frontiers in Cellular and Infection Microbiology 8.
Crossref
Crossref
Francesc Coll, Jody Phelan, Grant A. Hill-Cawthorne, Mridul B. Nair, Kim Mallard, Shahjahan Ali, Abdallah M. Abdallah, Saad Alghamdi, Mona Alsomali, Abdallah O. Ahmed, Stephanie Portelli, Yaa Oppong, Adriana Alves, Theolis Barbosa Bessa, Susana Campino, Maxine Caws, Anirvan Chatterjee, Amelia C. Crampin, Keertan Dheda, Nicholas Furnham, Judith R. Glynn, Louis Grandjean, Dang Minh Ha, Rumina Hasan, Zahra Hasan, Martin L. Hibberd, Moses Joloba, Edward C. Jones-López, Tomoshige Matsumoto, Anabela Miranda, David J. Moore, Nora Mocillo, Stefan Panaiotov, Julian Parkhill, Carlos Penha, João Perdigão, Isabel Portugal, Zineb Rchiad, Jaime Robledo, Patricia Sheen, Nashwa Talaat Shesha, Frik A. Sirgel, Christophe Sola, Erivelton Oliveira Sousa, Elizabeth M. Streicher, Paul Van Helden, Miguel Viveiros, Robert M. Warren, Ruth McNerney, Arnab Pain & Taane G. Clark. (2018) Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nature Genetics 50:2, pages 307-316.
Crossref
Crossref
Eduard Melief, Rachel Kokoczka, Megan Files, Mai Ann Bailey, Torey Alling, Hongye Li, James Ahn, Ayesha Misquith, Aaron Korkegian, David Roberts, James Sacchettini & Tanya Parish. (2018) Construction of an overexpression library for Mycobacterium tuberculosis. Biology Methods and Protocols 3:1.
Crossref
Crossref
Jan Zitko, Ondřej Jand'ourek, Pavla Paterová, Lucie Navrátilová, Jiří Kuneš, Jarmila Vinšová & Martin Doležal. (2018) Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold. MedChemComm 9:4, pages 685-696.
Crossref
Crossref
Muhammad Tahir Khan, Ashfaq Ur Rehaman, Muhammad Junaid, Shaukat Iqbal Malik & Dong-Qing Wei. (2018) Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance. Computational and Structural Biotechnology Journal 16, pages 379-387.
Crossref
Crossref
Pooja Gopal, Wilson Nartey, Priya Ragunathan, Jansy Sarathy, Firat Kaya, Michelle Yee, Claudia Setzer, Malathy Sony Subramanian Manimekalai, Véronique Dartois, Gerhard Grüber & Thomas Dick. (2017) Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infectious Diseases 3:11, pages 807-819.
Crossref
Crossref
Jean Claude Semuto Ngabonziza, Awa Ba Diallo, Elisa Tagliani, Bassirou Diarra, Abalo Essosimna Kadanga, Antieme Combo George Togo, Aliou Thiam, Willem Bram de Rijk, Riccardo Alagna, Sabine Houeto, Fatoumata Ba, Anoumou Yaotsè Dagnra, Emil Ivan, Dissou Affolabi, Valérie Schwoebel, Arnaud Trebucq, Bouke Catherine de Jong, Leen Rigouts & Géraldine Daneau. (2017) Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. PLOS ONE 12:10, pages e0187211.
Crossref
Crossref
Pavel Mucaji, Atanas G. Atanasov, Andrzej Bak, Violetta Kozik, Karolina Sieron, Mark Olsen, Weidong Pan, Yazhou Liu, Shengchao Hu, Junjie Lan, Norbert Haider, Robert Musiol, Jan Vanco, Marc Diederich, Seungwon Ji, Jan Zitko, Dongdong Wang, Danica Agbaba, Katarina Nikolic, Slavica Oljacic, Jelica Vucicevic, Daniela Jezova, Anna Tsantili-Kakoulidou, Fotios Tsopelas, Constantinos Giaginis, Teresa Kowalska, Mieczyslaw Sajewicz, Jerzy Silberring, Przemyslaw Mielczarek, Marek Smoluch, Izabela Jendrzejewska, Jaroslaw Polanski & Josef Jampilek. (2017) The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot †. Molecules 22:11, pages 1848.
Crossref
Crossref
Ghada Bouz, Martin Juhás, Pavlína Niklová, Ondřej Janďourek, Pavla Paterová, Jiří Janoušek, Lenka Tůmová, Zuzana Kovalíková, Petr Kastner, Martin Doležal & Jan Zitko. (2017) Ureidopyrazine Derivatives: Synthesis and Biological Evaluation as Anti-Infectives and Abiotic Elicitors. Molecules 22:10, pages 1797.
Crossref
Crossref
Julie Laborde, Céline Deraeve & Vania Bernardes‐Génisson. (2017) Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance. ChemMedChem 12:20, pages 1657-1676.
Crossref
Crossref
Lucia Semelková, Petra Janošcová, Carlos Fernandes, Ghada Bouz, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Lucie Navrátilová, Jiří Kuneš, Martin Doležal & Jan Zitko. (2017) Design, Synthesis, Antimycobacterial Evaluation, and In Silico Studies of 3-(Phenylcarbamoyl)-pyrazine-2-carboxylic Acids. Molecules 22:9, pages 1491.
Crossref
Crossref
Arfatur Rahman, Sara Sabrina Ferdous, Shahriar Ahmed, S. M. Mazidur Rahman, Mohammad Khaja Mafij Uddin, Suporn Pholwat, Jean Gratz, Eric Houpt & Sayera Banu. (2017)
Pyrazinamide Susceptibility and
pncA
Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh
. Antimicrobial Agents and Chemotherapy 61:9.
Crossref
Crossref
Ben Gold & Carl Nathan. 2017. Tuberculosis and the Tubercle Bacillus. Tuberculosis and the Tubercle Bacillus
317
360
.
Yumeng Zhang, Jia Zhang, Peng Cui, Ying Zhang & Wenhong Zhang. (2017) Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 61:8.
Crossref
Crossref
Nicholas A. Dillon, Nicholas D. Peterson, Heather A. Feaga, Kenneth C. Keiler & Anthony D. Baughn. (2017) Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA. Scientific Reports 7:1.
Crossref
Crossref
Pooja Gopal, Rokeya Tasneen, Michelle Yee, Jean-Philippe Lanoix, Jansy Sarathy, George Rasic, Liping Li, Véronique Dartois, Eric Nuermberger & Thomas Dick. (2017)
In Vivo-Selected Pyrazinoic Acid-Resistant
Mycobacterium tuberculosis
Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1
. ACS Infectious Diseases 3:7, pages 492-501.
Crossref
Crossref
Moses Njire, Na Wang, Bangxing Wang, Yaoju Tan, Xingshan Cai, Yanwen Liu, Julius Mugweru, Jintao Guo, H. M. Adnan Hameed, Shouyong Tan, Jianxiong Liu, Wing Wai Yew, Eric Nuermberger, Gyanu Lamichhane, Jinsong Liu & Tianyu Zhang. (2017) Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 61:7.
Crossref
Crossref
Ameeruddin Nusrath Unissa & Luke Elizabeth Hanna. (2017) Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. Tuberculosis 105, pages 96-107.
Crossref
Crossref
S. M. Ramirez-Busby, T. C. Rodwell, L. Fink, D. Catanzaro, R. L. Jackson, M. Pettigrove, A. Catanzaro & F. Valafar. (2017) A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Scientific Reports 7:1.
Crossref
Crossref
Xiangzhong Sun, Yaxin Li, Wenrong He, Chenggong Ji, Peixue Xia, Yichuan Wang, Shuo Du, Hongjiang Li, Natasha Raikhel, Junyu Xiao & Hongwei Guo. (2017) Pyrazinamide and derivatives block ethylene biosynthesis by inhibiting ACC oxidase. Nature Communications 8:1.
Crossref
Crossref
Jim Werngren, Erik Alm & Mikael Mansjö. (2017)
Non-
pncA
Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?
. Journal of Clinical Microbiology 55:6, pages 1920-1927.
Crossref
Crossref
Mohammad J. Nasiri, Mehri Haeili, Mona Ghazi, Hossein Goudarzi, Ali Pormohammad, Abbas A. Imani Fooladi & Mohammad M. Feizabadi. (2017) New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Frontiers in Microbiology 8.
Crossref
Crossref
Lucia Semelková, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Lucie Navrátilová, František Trejtnar, Vladimír Kubíček, Jiří Kuneš, Martin Doležal & Jan Zitko. (2017) 3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation. Molecules 22:3, pages 495.
Crossref
Crossref
Katarína Mikušová & Sean Ekins. (2017) Learning from the past for TB drug discovery in the future. Drug Discovery Today 22:3, pages 534-545.
Crossref
Crossref
Ben Gold & Carl Nathan. (2017)
Targeting Phenotypically Tolerant
Mycobacterium tuberculosis
. Microbiology Spectrum 5:1.
Crossref
Crossref
Ondrej Jandourek, Marek Tauchman, Pavla Paterova, Klara Konecna, Lucie Navratilova, Vladimir Kubicek, Ondrej Holas, Jan Zitko & Martin Dolezal. (2017) Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation. Molecules 22:2, pages 223.
Crossref
Crossref
Michelle Yee, Pooja Gopal & Thomas Dick. (2017) Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 61:2.
Crossref
Crossref
Brandon C. Rosen, Nicholas A. Dillon, Nicholas D. Peterson, Yusuke Minato & Anthony D. Baughn. (2017) Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 61:2.
Crossref
Crossref
Glenn P. Morlock, Frances C. Tyrrell, Dorothy Baynham, Vincent E. Escuyer, Nicole Green, Youngmi Kim, Patricia A. Longley-Olson, Nicole Parrish, Courtney Pennington, Desmond Tan, Brett Austin & James E. Posey. (2017)
Using Reduced Inoculum Densities of
Mycobacterium tuberculosis
in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation
. Tuberculosis Research and Treatment 2017, pages 1-9.
Crossref
Crossref
Md Mahmudul Islam, H.M. Adnan Hameed, Julius Mugweru, Chiranjibi Chhotaray, Changwei Wang, Yaoju Tan, Jianxiong Liu, Xinjie Li, Shouyong Tan, Iwao Ojima, Wing Wai Yew, Eric Nuermberger, Gyanu Lamichhane & Tianyu Zhang. (2017) Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Journal of Genetics and Genomics 44:1, pages 21-37.
Crossref
Crossref
Gail E. Louw & Samantha L. Sampson. 2017. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer
233
262
.
Joanna C. Evans, Carolina Trujillo, Zhe Wang, Hyungjin Eoh, Sabine Ehrt, Dirk Schnappinger, Helena I. M. Boshoff, Kyu Y. Rhee, Clifton E. BarryIIIIII & Valerie Mizrahi. (2016)
Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of
Mycobacterium tuberculosis
. ACS Infectious Diseases 2:12, pages 958-968.
Crossref
Crossref
Steven T. Pullan, Jon C. Allnutt, Rebecca Devine, Kim A. Hatch, Rose E. Jeeves, Charlotte L. Hendon-Dunn, Philip D. Marsh & Joanna Bacon. (2016) The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?. BMC Infectious Diseases 16:1.
Crossref
Crossref
Pooja Gopal, Michelle Yee, Jickky Sarathy, Jian Liang Low, Jansy P. Sarathy, Firat Kaya, Véronique Dartois, Martin Gengenbacher & Thomas Dick. (2016) Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infectious Diseases 2:9, pages 616-626.
Crossref
Crossref
Maha R. Farhat, Razvan Sultana, Oleg Iartchouk, Sam Bozeman, James Galagan, Peter Sisk, Christian Stolte, Hanna Nebenzahl-Guimaraes, Karen Jacobson, Alexander Sloutsky, Devinder Kaur, James Posey, Barry N. Kreiswirth, Natalia Kurepina, Leen Rigouts, Elizabeth M. Streicher, Tommie C. Victor, Robin M. Warren, Dick van Soolingen & Megan Murray. (2016)
Genetic Determinants of Drug Resistance in
Mycobacterium tuberculosis
and Their Diagnostic Value
. American Journal of Respiratory and Critical Care Medicine 194:5, pages 621-630.
Crossref
Crossref
Alice L. den Hertog, Sandra Menting, Richard Pfeltz, Matthew Warns, Salman H. Siddiqi & Richard M. Anthony. (2016) Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature. Antimicrobial Agents and Chemotherapy 60:8, pages 4956-4960.
Crossref
Crossref
Bharati Pandey, Sonam Grover, Chetna Tyagi, Sukriti Goyal, Salma Jamal, Aditi Singh, Jagdeep Kaur & Abhinav Grover. (2016) Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis. Gene 581:1, pages 31-42.
Crossref
Crossref
Yunting Gu, Xia Yu, Guanglu Jiang, Xiaobo Wang, Yifeng Ma, Yunxu Li & Hairong Huang. (2016) Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagnostic Microbiology and Infectious Disease 84:3, pages 207-211.
Crossref
Crossref
Moses Njire, Yaoju Tan, Julius Mugweru, Changwei Wang, Jintao Guo, WingWai Yew, Shouyong Tan & Tianyu Zhang. (2016) Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Advances in Medical Sciences 61:1, pages 63-71.
Crossref
Crossref
Nicholas D. Peterson, Brandon C. Rosen, Nicholas A. Dillon & Anthony D. Baughn. (2015) Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 59:12, pages 7320-7326.
Crossref
Crossref
Dmitry A. Maslov, Marina V. Zaĭchikova, Larisa N. Chernousova, Kirill V. Shur, Olga B. Bekker, Tatiana G. Smirnova, Elena E. Larionova, Sofya N. Andreevskaya, Ying Zhang & Valery N. Danilenko. (2015) Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960. Tuberculosis 95:5, pages 608-612.
Crossref
Crossref